Receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent.
Receive immunization with attenuated live vaccines (seasonal flu shot)1 week before starting this .
Show evidence of disease (cancer).
Uncontrolled medical conditions such as: unstable angina, congestive heart failure, diabetes, severely impaired lung function.
Liver disease such as cirrhosis, severe hepatic impairment, Hepatitis B or C.
Active, uncontrolled severe infections
Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.
Known History of HIV positivity.
Impaired gastrointestinal function that may alter absorption of Everolimus such as ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection.
Patients with an active, bleeding diathesis.
Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. )
Male patient whose sexual partner(s) are Women of child bearing potential who are not willing to use adequate.
contraception, during the study and for 8 weeks after the end of treatment
Patients who have received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus).
Patients with a known hypersensitivity to Everolimus or other rapamycin analogues (sirolimus, temsirolimus) or to its excipients.
History of noncompliance to medical regimens.
Patients unwilling to or unable to comply with the protocol.
